




Multiple Sclerosis Agents Prior Authorization

Drug(s) Applied:	Betaseron (Interferon beta-1b), Plegridy (peginterferon beta-1a)
-------------------------	--

Criteria:

Drug(s) Applied will be approved when the requested medication is being used for an FDA approved indication and all of the following criteria are met:

I. Initial Therapy Criteria

A. Relapsing Multiple Sclerosis as indicated by chart notes within past 180 days


1. Diagnosis of relapsing multiple sclerosis (relapsing-remitting (RRMS) or secondary progressive (SPMS)) **and**
2. If for SPMS, patient is ambulatory **and**
3. Patient will NOT be using the requested agent concomitantly with other disease modifying MS agents (such as alemtuzumab (Lemtrada), cladribine (Mavenclad), dimethyl fumarate (Tecfidera), fingolimod (Gilenya), glatiramer acetate (Glatopa, Copaxone), interferon beta, natalizumab (Tysabri), ocrelizumab (Ocrevus), siponimod (Mayzent), and teriflunomide (Aubagio)); with exception of an agent used in combination with Mavenclad (cladribine) and the prescriber has provided justification for combination use (e.g., using DMT for relapse between cycles of Mavenclad) **and**
4. Prescribed by or in consultation with a neurologist

Approval Duration: 12 months

II. Continued Therapy Criteria

A. Relapsing Multiple Sclerosis as indicated by chart notes within past 12 months

1. Patient meets the initial therapy criteria above **and**
2. If for SPMS, patient is ambulatory **and**
3. Documented clinical benefit since starting the requested agent (i.e., disease stability or improvement) **and**
4. Patient will NOT be using the requested agent concomitantly with other disease modifying MS agents (such as alemtuzumab (Lemtrada), cladribine (Mavenclad), dimethyl fumarate (Tecfidera), fingolimod (Gilenya), glatiramer acetate (Glatopa, Copaxone), interferon beta, natalizumab (Tysabri), ocrelizumab (Ocrevus), siponimod (Mayzent), and teriflunomide (Aubagio)); with exception of an agent used in combination with Mavenclad (cladribine) and the prescriber has provided



justification for combination use (e.g., using DMT for relapse between cycles of Mavenclad)

Approval Duration: 12 months

References:

1. Avonex prescribing information. Biogen, Inc. March 2024.
2. Betaseron prescribing information. Bayer HealthCare Pharmaceuticals, Inc. Sept 2025.
3. Glatopa prescribing information. Sandoz Inc. March 2024.
4. Plegridy prescribing information. Biogen, Inc. July 2023.
5. Multiple Sclerosis Coalition. The Use of Disease Modifying Therapies in Multiple Sclerosis: Principals and Current Evidence. Updated June 2019. National Multiple Sclerosis Society. Available at:
https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/DMT_Consensus_MS_Coalition.pdf.
6. Institute for Clinical and Economic Review (ICER). Oral and Monoclonal Antibody Treatments for Relapsing Forms of Multiple Sclerosis: Effectiveness and Value. February 21, 2023.
7. Rae-Grant, Alexander, MD, et al. Practice Guideline Recommendations: Disease-Modifying Therapies for Adults with Multiple Sclerosis. Neurology. 2018;90:777-788. Reaffirmed October 2024. <https://www.aan.com/Guidelines/home/GuidelineDetail/898>.
8. Corboy, John R, MD, et al. Comment on 2018 American Academy of Neurology Guidelines on Disease-Modifying Therapies in MS. Neurology. 2018;90:1106-1112.
9. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17:162-73.
10. National Multiple Sclerosis Society 2017 McDonald MS Diagnostic Criteria. Available at: <https://www.nationalmssociety.org/For-Professionals/Clinical-Care/Diagnosing-MS/Diagnosing-Criteria>.
11. Conway D, Cohen JA. Combination therapy in multiple sclerosis. Lancet Neurol 2010 Mar;9(3):299-308.
12. Freedman MS, Devonshire V, Duquette P, et al. Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. The Can J Neurol Sci. 2020;47:437-455.
13. National Institute for Health and Care Excellence. NICE Guidance - Conditions and diseases - Neurological conditions - Multiple sclerosis. Ofatumumab for treating relapsing multiple sclerosis. Technology appraisal guidance [TA699] Published: 19 May 2021. Accessed at 3 Committee discussion | Ofatumumab for treating relapsing multiple sclerosis | Guidance | NICE.

Policy Owned by: Curative PBM team